REVIEW PAPER
Certolizumab pegol – new option in the treatment of psoriatic arthritis
Submission date: 2014-05-22
Acceptance date: 2014-06-24
Online publication date: 2014-07-31
Publication date: 2014-06-30
Reumatologia 2014;52(3):181-188
KEYWORDS
TOPICS
Spondyloarthropaties - aetiology, pathogenesis clinical features and treatmentNew therapies in rheumatic diseases
ABSTRACT
It has been proven that tumor necrosis factor (TNF) plays an important role in the pathophysiology of psoriatic arthritis (PsA). TNF inhibitors have been demonstrated to improve the skin and joint manifestations of psoriasis. New possibilities of treatment of the disease have appeared due to availability of biological drugs which are TNF inhibitors. Among the first TNF inhibitors that have been used to treat PsA were etanercept, adalimumab, infliksymab. Due to primary and secondary ineffectiveness of the therapy occurring in large numbers of PsA patients investigations are going on in order to develop new, more effective, safer and more convenient methods to treat PsA. Such a new therapeutic possibility is offered by the new generation TNF inhibitor with a molecular structure different from other TNF inhibitors – certolizumab pegol (CZP).In this article the results of clinical studies concerning the application of CZP in PsA treatment are presented.
REFERENCES (23)
1.
Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev 2014; 13: 490-495. .
2.
Przepiera-Będzak H, Brzosko I. Łuszczycowe zapalenie stawów. W: Wielka Interna, red. M. Puszczewicz. Med po Dypl 2011: 259-265. .
3.
Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs 2000; 9: 1511-1522. .
4.
Chimenti MS, Saraceno R, Chiricozzi A, et al. Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Design Dev Therapy 2013; 7: 339-348. .
5.
Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2 year data from the Adalimumab effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009; 68: 702-709. .
6.
Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomized double blind multicentre trial. BMJ 2010; 340: c147. .
7.
Kavanaugh A, Mease P, Krueger GG, et al. on behalf of the GO-REVEAL Study Group. Golimumab, a new human, TNF-αlpha antibody, administered subcutaneously every four weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized,placebo – controlled GO-REVEAL Study. Ann Rheum Dis 2009; 68 (suppl 3): 136. .
8.
Antoni C, Kavanaugh A, Kirham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Trial. Arthritis Rheum 2005; 52: 1227-1236. .
9.
Kavanaugh A, Krueger GG, Beutler A, et al. For the IMPACT 2 study group. Infliximab sustains a higher degree of clinical response trough one year of treatment: results from the IMPACT II trial. Ann Rheum Dis 2007; 66: 498-505. .
10.
Wiland P, Świerkot J, Maśliński W. Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów. Reumatologia 2011; 49: 253-263. .
12.
Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13: 1323-1332. .
13.
Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673. .
14.
Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4-12. .
15.
Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014; 73: 6-16. .
16.
Wiland P, Szechiński J, Filipowicz-Sosnowska A i wsp. Rekomendacje stosowania blokerów TNF- u chorych na łuszczycowe zapalenie stawów. Reumatologia 2004; 42: 403-411. .
17.
Punzi L, Podswiadek M, Sfriso P, et al. Pathogenetic and clinical rationale for TNF-βlocking therapy in psoriatic arthritis. Autoimmun Rev 2007; 6: 524-528. .
18.
Gisondi P, Girolomoni G. Biologic therapies in psoriasis: A new therapeutic approach. Autoimmun Rev 2007; 6: 515-519. .
19.
Weinblatt M, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the phase IIIb REALISTIC study. Rheumatology 2012; 51: 2204-2214. .
20.
Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. British Assoc Dermatol 2012; 167: 180-190. .
21.
Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014; 73: 48-55. .
22.
Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis 2014; 73: 233-237. .
23.
Gladman D, Fleischmann R, Coteur RG, et al. Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-WeekPatient-Reported Outcome Results of the RAPID-PsA Study. Arthritis Care Res 2014, 2013 Dec 10. doi: 10.1002/acr.22256. [Epub ahead of print].
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
